Skip to main content
Equibles
URGN logo

URGN · UroGen Pharma Ltd. · Webcasts, Transcripts & Audio

Track URGN — free

Use URGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research URGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$40.55 -0.08 (-0.20%) At close · Oct 1
Russell 2000 member Rebalance outlook locked
Market Cap
$2.02B
Shares
48.88M
Volume · Oct 1 624.62K Avg daily vol (3M) 829.88K

UroGen Pharma Ltd. Webcasts

Earnings calls, investor updates, investor days and conferences for UroGen Pharma Ltd. (URGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲41.8% $16.10M −$25.83M '22 Q3 22-11-10 ▲11.9% $18.09M −$28.87M '22 Q4 23-03-22 ▲26.7% $17.19M −$30.21M '23 Q1 23-05-11 ▲27.3% $21.14M −$24.14M '23 Q2 23-08-10 ▲29.5% $20.85M −$21.88M '23 Q3 23-11-14 ▲30.1% $23.53M −$26.02M '23 Q4 24-03-14 ▲9.2% $18.78M −$32.29M '24 Q1 24-06-13 ▲3.4% $21.85M −$33.40M '24 Q2 24-08-13 ▲20.9% $25.20M −$23.67M '24 Q3 24-11-06 ▲4.4% $24.57M −$37.51M '24 Q4 25-03-10 ▲7.8% $20.25M −$43.84M '25 Q1 25-05-12 ▲10.8% $24.21M −$49.94M '25 Q2 25-08-07 ▲9% $27.48M −$33.35M '25 Q3 25-11-06 ▲54% $37.84M −$26.36M '25 Q4 26-03-02 ▲151.6% $50.96M −$23.57M '26 Q1 26-05-06 LATEST ▲199.2% $72.46M −$14.35M '26 Q2 26-08-05
Conference
Investor event
2026-09-15
UroGen Pharma Ltd. (URGN) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
UroGen Pharma Ltd. (URGN) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
Confident tone Pipeline progression (UGN-103, UGN-104, UGN-501) Envision Phase 3 durability data Community practice adoption expansion
Revenue
$72.46M
▲ 199.2% YoY
Gross margin
90.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-19
UroGen Pharma Ltd. (URGN) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Confident tone ZUSDURI launch momentum JELMYTO outlook Community setting adoption
Revenue
$50.96M
▲ 151.6% YoY
Gross margin
91.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Confident tone Zysturi commercial launch UGN-103 next-generation pipeline UGN-104 Jelmyto next-generation
Revenue
$37.84M*
▲ 54% YoY
Gross margin
91.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Positive tone ZUSDURI launch JELMYTO commercial performance UGN-103 next-generation mitomycin
Revenue
$27.48M
▲ 9% YoY
Gross margin
88.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
Confident tone Patient demand and eligible patient pool Zesturi (Jesduvriq) commercial launch and revenue growth Physician adoption and KOL feedback
Revenue
$24.21M
▲ 10.8% YoY
Gross margin
85.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript
Confident tone UGN-102 regulatory progress and ODAC UGN-102 commercial launch readiness JELMYTO commercial performance
Revenue
$20.25M
▲ 7.8% YoY
Gross margin
88.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript
Confident tone UGN-102 NDA and regulatory progress JELMYTO commercial performance ENVISION trial data and durability
Revenue
$24.57M
▲ 4.4% YoY
Gross margin
89.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
Confident tone UGN-102 NDA progress and potential approval JELMYTO commercial performance Advisory committee preparation
Revenue
$25.20M
▲ 20.9% YoY
Gross margin
90.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
Positive tone UGN-102 pivotal data and NDA submission JELMYTO commercial performance Gross-to-net and reimbursement headwinds
Revenue
$21.85M
▲ 3.4% YoY
Gross margin
89.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-06-13
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
Confident tone UGN-102 regulatory and commercial opportunity JELMYTO commercial performance High-grade disease and UGN-301 program
Revenue
$18.78M
▲ 9.2% YoY
Gross margin
90.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
Confident tone UGN-102 regulatory and commercial opportunity Clinical trial data (ATLAS, ENVISION, OPTIMA) JELMYTO commercial performance
Revenue
$23.53M
▲ 30.1% YoY
Gross margin
90.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
UroGen Pharma Ltd. (URGN) Q3 2023 Earnings Call Transcript
Revenue
$20.85M
▲ 29.5% YoY
Gross margin
88.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
UroGen Pharma Ltd. (URGN) Q2 2023 Earnings Call Transcript
Revenue
$21.14M
▲ 27.3% YoY
Gross margin
88.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
UroGen Pharma Ltd. (URGN) Q1 2023 Earnings Call Transcript
Revenue
$17.19M
▲ 26.7% YoY
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-22
UroGen Pharma Ltd. (URGN) Q4 2022 Earnings Call Transcript
Revenue
$18.09M*
▲ 11.9% YoY
Gross margin
87.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
UroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call Transcript
Revenue
$16.10M
▲ 41.8% YoY
Gross margin
87.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
UroGen Pharma Ltd. (URGN) Q2 2022 Earnings Call Transcript
Revenue
$16.60M
▲ 27.4% YoY
Gross margin
88.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
UroGen Pharma Ltd. (URGN) Q1 2022 Earnings Call Transcript
Revenue
$13.56M
▲ 81.2% YoY
Gross margin
88.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-21
UroGen Pharma Ltd. (URGN) Q4 2021 Earnings Call Transcript
Revenue
$16.17M*
Gross margin
90.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
UroGen Pharma Ltd. (URGN) Q3 2021 Earnings Call Transcript
Revenue
$11.35M
▲ 228% YoY
Gross margin
89.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-14
UroGen Pharma Ltd. (URGN) Q2 2021 Earnings Call Transcript
Revenue
$13.03M
▲ 3403.2% YoY
Gross margin
89.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
UroGen Pharma Ltd. (URGN) Q1 2021 Earnings Call Transcript
Revenue
$7.49M
Gross margin
88.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-18
UroGen Pharma Ltd. (URGN) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
UroGen Pharma Ltd. (URGN) Q3 2020 Earnings Call Transcript
Revenue
$3.46M
Gross margin
91.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
UroGen Pharma Ltd. (URGN) Q2 2020 Earnings Call Transcript
Revenue
$372,000
▲ 1966.7% YoY
Gross margin
87.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
UroGen Pharma Ltd. (URGN) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–29 of 29 webcasts
Key facts CIK 1668243 CUSIP M96088105 13F (30d) 6 filings 6 filers Visit website Investor relations